Role of implantable cardioverter defibrillator therapy in patients with acquired long QT syndrome: A long-term follow-up

Europace

Volumn 14, Issue 3, 2012, Pages 396-401

  Mönnig, Gerold ^a   Köbe, Julia ^a   Löher, Andreas ^a   Wasmer, Kristina ^a   Milberg, Peter ^a   Zellerhoff, Stephan ^a   Pott, Christian ^a   Zumhagen, Sven ^a   Radu, Razvan ^a   Scheld, Hans H ^a   Haverkamp, Wilhelm ^b   Schulze Bahr, Eric ^a   Eckardt, Lars ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Acquired long QT syndrome; Implantable cardioverter defibrillator; Long term follow up; Outcome

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CONTRAST MEDIUM; HALOPERIDOL;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BRADYCARDIA; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; DEFIBRILLATOR; DRUG ABUSE; FEMALE; FOLLOW UP; HEART ARREST; HUMAN; HYPOKALEMIA; LONG QT SYNDROME; MALE; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84857888958     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eur316     Document Type: Article

References (26)

1. Roden DM. Acquired long QT syndromes and the risk of proarrhythmia. J Cardiovasc Electrophysiol 2000;11:938-40. (Pubitemid 30663004)
2. Eckardt L, Haverkamp W, Borggrefe M, Breithardt G. Experimental models of torsade de pointes. Cardiovasc Res 1998;39:178-93. (Pubitemid 28322389)
3. Zareba W. Drug induced qt prolongation. Cardiol J 2007;14:523-33. (Pubitemid 351278615)
4. Roden DM. Repolarization reserve: A moving target. Circulation 2008;118:981-2.
5. Milberg P, Fleischer D, Stypmann J, Osada N, Mönnig G, Engelen MA et al. Reduced repolarization reserve due to anthracycline therapy facilitates torsade de pointes induced by ikr blockers. Basic Res Cardiol 2007;102:42-51. (Pubitemid 44932770)
6. Chiang CE. Congenital and acquired long QT syndrome. Current concepts and management. Cardiol Rev 2004;12:222-34.
7. Haverkamp W, Mönnig G, Schulze-Bahr E, Haverkamp F, Breithardt G. Physician-induced torsade de pointes-therapeutic implications. Cardiovasc Drugs Ther 2002;16:101-9.
8. Priori SG, Aliot E, Blomstrom-Lundqvist C, Bossaert L, Breithardt G, Brugada P et al. Update of the guidelines on sudden cardiac death of the European society of cardiology. Eur Heart J 2003;24:13-5. (Pubitemid 36109541)
9. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M et al. ACC/ AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death-executive summary: A report of the American college of cardiology/American heart association task force and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European heart rhythm association and the heart rhythm society. Eur Heart J 2006;27:2099-140.
10. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome. An update. Circulation 1993;88:782-4. (Pubitemid 23228078)
11. Vardas PE, Auricchio A, Blanc JJ, Daubert JC, Drexler H, Ector H et al. Guidelines for cardiac pacing and cardiac resynchronization therapy: The task force for cardiac pacing and cardiac resynchronization therapy of the European society of cardiology. Developed in collaboration with the European heart rhythm association. Eur Heart J 2007;28:2256-95. (Pubitemid 47428944)
12. Mönnig G, Eckardt L, Wedekind H, Haverkamp W, Gerss J, Milberg P et al. Electrocardiographic risk stratification in families with congenital long QT syndrome. Eur Heart J 2006;27:2074-80. (Pubitemid 44412814)
13. Bazett HC. An analysis of the time-relation of electrocardiograms. Heart 1920;7: 353-70.
14. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA 2003;289:2120-7. (Pubitemid 37430214)
15. Davey PP, Barlow C, Hart G. Prolongation of the qt interval in heart failure occurs at low but not at high heart rates. Clin Sci (Lond) 2000;98:603-10. (Pubitemid 30261011)
16. Gaudron P, Kugler I, Hu K, Bauer W, Eilles C, Ertl G. Time course of cardiac structural, functional and electrical changes in asymptomatic patients after myocardial infarction: Their inter-relation and prognostic impact. J Am Coll Cardiol 2001;38:33-40. (Pubitemid 32613825)
17. Haverkamp W, Mönnig G, Kirchhof P, Eckardt L, Borggrefe M, Breithardt G. Torsade de pointes induced by ajmaline. Z Kardiol 2001;90:586-90. (Pubitemid 32778153)
18. van Noord C, van der Deure WM, Sturkenboom MC, Straus SM, Hofman A, Visser TJ et al. High free thyroxine levels are associated with QTc prolongation in males. J Endocrinol 2008;198:253-60. (Pubitemid 352038204)
19. Staudacher I, Schweizer PA, Katus HA, Thomas D. Herg: Protein trafficking and potential for therapy and drug side effects. Curr Opin Drug Discov Devel 2010;13: 23-30.
20. Roden DM. Drug-induced prolongation of the qt interval. N Engl J Med 2004;350: 1013-22. (Pubitemid 38269278)
21. Arking DE, Pfeufer A, Post W, Kao WH, Newton-Cheh C, Ikeda M et al. A common genetic variant in the nos1 regulator nos1ap modulates cardiac repolarization. Nat Genet 2006;38:644-51. (Pubitemid 43927305)
22. Newton-Cheh C, Eijgelsheim M, Rice KM, de Bakker PI, Yin X, Estrada K et al. Common variants at ten loci influence qt interval duration in the qtgen study. Nat Genet 2009;41:399-406.
23. Newton-Cheh C, Larson MG, Corey DC, Benjamin EJ, Herbert AG, Levy D et al. Qt interval is a heritable quantitative trait with evidence of linkage to chromosome 3 in a genome-wide linkage analysis: The Framingham heart study. Heart Rhythm 2005;2:277-84. (Pubitemid 40309826)
24. Newton-Cheh C, Guo CY, Larson MG, Musone SL, Surti A, Camargo AL et al. Common genetic variation in kcnh2 is associated with qt interval duration: The Framingham heart study. Circulation 2007;116:1128-36. (Pubitemid 47360215)
25. Mönnig G, Köbe J, Löher A, Eckardt L, Wedekind H, Scheld HH et al. Implantable cardioverter-defibrillator therapy in patients with congenital long-QT syndrome: A long-term follow-up. Heart Rhythm 2005;2:497-504. (Pubitemid 40521363)
26. Schwartz PJ, Spazzolini C, Priori SG, Crotti L, Vicentini A, Landolina M et al. Who are the long-qt syndrome patients who receive an implantable cardioverterdefibrillator and what happens to them?: Data from the European long-qt syndrome implantable cardioverter-defibrillator (LQTS ICD) registry. Circulation 2010;122:1272-82.